XML 12 R46.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Legal Proceedings (Details) (USD $) | 3 Months Ended | 6 Months Ended | 3 Months Ended | 1 Months Ended
--- | --- | --- | --- | ---
Jul. 03, 2011 | Jan. 02, 2011 | Jul. 01, 2012 | Jan. 02, 2011 Restitution [Member] | Jan. 02, 2011 Average Wholesale Price Litigation [Member] Civil penalties [Member] | Jul. 03, 2011 Risperdal [Member] Civil penalties [Member] | Jul. 01, 2012 Levaquin [Member] claimants | Jul. 01, 2012 ASR [Member] claimants | Jul. 01, 2012 Pinnacle Acetabular Cup System [Member] claimants | Jul. 01, 2012 Risperdal [Member] claimants | Jul. 01, 2012 Pelvic Meshes [Member] claimants | Jul. 01, 2012 Duragesic [Member] claimants | Jul. 01, 2012 Topamax [Member] claimants | Apr. 30, 2012 Risperdal [Member]
Legal Proceeding (Textuals) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Liability Contingency Number Of Claimants |  |  |  |  |  |  | 3,400 | 7,200 | 1,700 | 420 | 1,400 | 35 | 60 |
Amount given to plaintiff by jury | $ 482,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Verdict Against Company | 593,000,000 |  | 257,700,000 |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement Pre Judgment Interest | 111,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Assessed damages for alleged consumer fraud as to DURAGESIC and RISPERDAL |  | 4,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Net litigation expense |  |  | 73,000,000 |  |  |  |  |  |  |  |  |  |  |
Litigation Loss |  |  |  | 45,000,000 | 6,500,000 | 327,100,000 |  |  |  |  |  |  |  |
Civil Penalties |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,200,000,000

X
- Definition Amount given to plaintiff by jury. + References No definition available. + Details
Name: | jnj_AmountGivenToPlaintiffByJury
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Assessed Damages for Alleged Consumer Fraud as to DURAGESIC and RISPERDAL. + References No definition available. + Details
Name: | jnj_AssessedDamagesForAllegedConsumerFraudRelatedToCertainDrugs
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Civil Penalties + References No definition available. + Details
Name: | jnj_CivilPenalties
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | jnj_LegalProceedingTextualsAbstract
Namespace Prefix: | jnj_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation loss. + References No definition available. + Details
Name: | jnj_LitigationLoss
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Litigation settlement pre judgment interest. + References No definition available. + Details
Name: | jnj_LitigationSettlementPreJudgmentInterest
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Product liability contingency number of claimants. + References No definition available. + Details
Name: | jnj_ProductLiabilityContingencyNumberOfClaimants
Namespace Prefix: | jnj_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Verdict in favor of the State's Attorney General and against Janssen and the Company. + References No definition available. + Details
Name: | jnj_VerdictAgainstCompany
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This element represents the expenses incurred by the entity which are directly related and attributable to receiving an award in settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration